Please login to the form below
insulin degludec
This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk preps for speedy oral GLP-1 drug filing
Group sales barely moved in 2018 compared to the prior year, coming in at 112bn krone, with the GLP-1 portfolio’s growth offsetting declines in insulin products. ... 10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a
Latest news
-
Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity
Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
-
Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1
Victoza’s performance meant that Novo Nordisk was able to weather the pressure in the insulins market, which kept its overall insulin sales flat at DKK 14.66bn. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which
-
CHMP backs first-line use for AZ’s Tagrisso in lung cancer
insulin degludec/liraglutide).
-
Novo seeks to strengthen Tresiba label in US
Studies find insulin degludec advantage over insulin glargine. Novo Nordisk has filed new data to the FDA showing its long-acting insulin Tresiba is less likely to cause low blood sugar ... The Danish drugmaker wants the results of the DEVOTE trial -
-
Sanofi wins EU approval for new diabetes combination Suliqua
The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo
More from news
Approximately 12 fully matching, plus 55 partially matching documents found.
Latest Intelligence
-
Interview: Peter Meeus, Novo Nordisk
Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- FDA hands BMS and bluebird bio a priority review for ide-cel
- 20 for 2020 – Five pharma companies to watch
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
claire@dovetailstrategies.com
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
